CORT — CORCEPT THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1088856 ·
Last close
$83.12
Market Cap
$8.92B
52W High
$84.79
52W Low
$32.04
ADV30
1,113,175
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 164,903,000 | 162,020,000 | -49,601,000 | -31,761,000 | 814,881,000 | 108,738,000 | 176,894,000 |
| Dec 2025 | 202,125,000 | 199,580,000 | 4,487,000 | 24,288,000 | 836,651,000 | 120,495,000 | 188,846,000 |
| Sep 2025 | 207,638,000 | 203,042,000 | 10,219,000 | 19,668,000 | 823,607,000 | 125,138,000 | 191,705,000 |
| Jun 2025 | 194,430,000 | 190,997,000 | 26,675,000 | 35,149,000 | 801,722,000 | 102,745,000 | 165,929,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$120,454,000
Investing CF
$77,471,000
Financing CF
$-179,803,000
CapEx
$-412,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$611,626,000
Inventory
$12,890,000
Receivables
$39,072,000
ST Investments
$229,446,000
EBIT TTM
$-49,601,000
Pretax Income TTM
$12,130,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$769,096,000
EBITDA
$-6,935,000
Free Cash Flow
$115,660,496
Enterprise Value
$8,571,973,632
Total Cash
$338,184,000
Total Debt
$9,637,000
Shares Out
107,351,594
Trailing EPS
$0.35
Book Value
$5.94
ROE
7.2%
ROA
-0.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 761,407,000 | 44,797,000 | 99,652,000 | 836,651,000 | 188,846,000 | — | 141,996,000 |
| Dec 2024 | 675,040,000 | 136,951,000 | 141,209,000 | 840,553,000 | 160,964,000 | — | 198,295,000 |
| Dec 2023 | 482,375,000 | 107,282,000 | 106,140,000 | 621,517,000 | 114,812,000 | — | 126,681,000 |
| Dec 2022 | 401,858,000 | 112,634,000 | 101,418,000 | 583,430,000 | 81,588,000 | — | 120,323,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$10,102,000
NetIncome TTM
$-4,830,000
OpCashFlow TTM
$0
Assets (Latest)
$51,902,000
Forward EPS
$2.50
Max Pain — expiry 2026-06-18
max pain strike: $50.00 · spot: $83.12 · call oi: 4,396 · put oi: 1,804Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | $9.07B | $123.35 | — |
| CYTK | CYTOKINETICS INC | $9.69B | $71.38 | — |
| ABVX | Abivax S.A. | $7.83B | $98.26 | — |
| TGTX | TG THERAPEUTICS, INC. | $7.70B | $50.30 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.76B | $55.65 | — |
News headlines (Yahoo Finance, 1h cache)
June 2026's Leading Growth Stocks With Strong Insider Ownership
2026-06-15 17:36 · Yahoo
Esquire Financial Holdings And 2 Insider Picks For Growth Potential
2026-06-15 11:36 · Yahoo
Spotlight On June 2026's Insider-Favored Growth Stocks
2026-06-12 17:35 · Yahoo
3 Growth Companies Insiders Are Betting On
2026-06-12 11:35 · Yahoo
3 Growth Companies With Insider Ownership Up To 23%
2026-06-11 11:36 · Yahoo
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)
2026-06-11 10:20 · Yahoo
Insider Favorites: Top Growth Companies For June 2026
2026-06-10 17:35 · Yahoo
Top Growth Companies With Insider Ownership In June 2026
2026-06-10 11:35 · Yahoo
ATRenew And Two Insider-Favored Growth Stocks To Watch
2026-06-09 17:36 · Yahoo
3 Growth Stocks With High Insider Ownership And 29% Revenue Growth
2026-06-09 11:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.